Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics (Nasdaq: PSTV) has secured a significant national coverage agreement with UnitedHealthcare Insurance Company for its CNSide® Cerebrospinal Fluid Tumor Cell Enumeration test. The agreement, effective September 15, 2025, extends coverage to over 51 million people across the United States.
The CNSide® CSF Assay Platform, which has demonstrated 92% sensitivity and 95% specificity, aids in diagnosing and monitoring patients with leptomeningeal metastases. The test has been validated through 9 peer-reviewed publications and the FORESEE clinical trial, with over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020, influencing treatment decisions in 90% of cases.
Plus Therapeutics (NASDAQ:PSTV) has received a $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded $17.6 million grant. This marks the second non-dilutive payment following a $1.6 million receipt in July 2025.
The funding will support the clinical development of REYOBIQ™ for the ReSPECT-LM dose optimization trial and the development of CNSide LM diagnostic test. The company expects an additional $1.9 million in funding over the next 12 months. Plus Therapeutics maintains active grants from the National Institutes of Health and Department of Defense, demonstrating strong institutional support for its clinical programs.
Plus Therapeutics (Nasdaq: PSTV) announced that its subsidiary, CNSide Diagnostics, has received CMS accreditation for its Houston-based laboratory. The certification confirms compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations for testing human specimens.
The accreditation is a crucial milestone for the broader market release of the CNSide cerebrospinal fluid (CSF) assay platform, designed for patients with or at risk for CNS cancers. This achievement enables state licensure in 48 states, broad commercial insurance coverage, access to government payor coverage, and expansion of payment coding opportunities.
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025.
The company's President and CEO, Marc H. Hedrick, M.D., will engage in a fireside chat with H.C. Wainwright's VP of Equity Research, Sean Lee. The discussion will be available on demand starting September 5, 2025, at 7:00 AM ET for registered conference attendees.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has regained compliance with Nasdaq listing requirements. The company received confirmation from Nasdaq on August 22, 2025, verifying compliance with two key criteria: maintaining a market value of listed securities above $35 million and stockholders' equity exceeding $2.5 million.
As a result, PSTV has been granted an extended grace period until November 12, 2025, to meet the $1.00 bid price requirement, replacing the previous September 8 deadline. The company remains under panel monitoring for the Equity Standard through August 22, 2026.
Plus Therapeutics (NASDAQ:PSTV) announced positive results from its ReSPECT-LM Phase 1 trial for REYOBIQ™ in treating leptomeningeal metastases (LM). The trial, involving 29 subjects across 6 cohorts, demonstrated significant efficacy with a 76% radiographic and 87% clinical response rate through day 112.
Key outcomes include 100% reduction in CSF tumor cells at day 28, with five of seven patients showing >80% tumor cell reduction surviving at least one year. The median overall survival reached 9 months, substantially better than the typical 4-month survival rate. The study established a recommended Phase 2 single dose of 44.1 mCi, with no dose-limiting toxicities in cohorts 1-4 and manageable safety profile in higher doses.
[ "Clinical benefit rate exceeded 75% in 3 key outcome measures", "Median overall survival of 9 months vs typical 4 months in literature", "100% reduction in CSF tumor cells observed at day 28", "Favorable safety profile with majority of adverse events being Grade 1 and 2", "Five of seven patients with >80% tumor cell reduction survived at least 1 year" ]Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for CNS cancers, has successfully addressed its Nasdaq listing compliance concerns. The company reported stockholders' equity of $3 million as of June 30, 2025, exceeding the minimum requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1).
This development follows a period of non-compliance identified on June 3, 2025, which led to a hearing before the Nasdaq Hearings Panel on July 15, 2025. The Panel granted Plus an extension to demonstrate compliance, and the company's recent Form 10-Q filing on August 14, 2025, confirms its return to compliance with the Equity Rule.
Plus Therapeutics (NASDAQ:PSTV) reported Q2 2025 financial results and significant progress in its CNS cancer treatment programs. The company achieved net income of $5.2 million ($0.02 per share), compared to a net loss of $2.9 million in Q2 2024, primarily due to derivative instruments valuation changes. Cash position strengthened to $6.9 million as of June 30, 2025.
Key developments include the initiation of the REYOBIQ dose optimization trial for leptomeningeal metastases treatment and FDA clearance for pediatric brain cancer treatment. The company also announced the commercial launch of its CNSide CSF assay platform in Texas, targeting a $6 billion U.S. market, with plans for national expansion. Additionally, Plus completed restructuring of its $15 million equity financing and received a $1.6 million CPRIT grant payment.
Plus Therapeutics (NASDAQ:PSTV) presented positive data from their CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 SNO/ASCO CNS Metastases Conference. The retrospective analysis, involving 613 CNSide assays from 218 patients across 5 institutions, demonstrated significant capabilities in detecting and monitoring leptomeningeal metastases (LM).
Key findings include 67% detection rate of CSF tumor cells, with notable observations of immunocytochemistry and FISH probe detection changes in patients with multiple CSF draws. The platform showed 2.8 times higher diagnostic sensitivity compared to standard CSF cytology and influenced clinical management decisions in over 90% of LM cases.
Plus Therapeutics (NASDAQ:PSTV) announced the commercial launch of its CNSide® diagnostic platform in Texas starting August 2025. The CNSide cerebrospinal fluid assay platform will initially focus on NCI-Designated Cancer Centers, including UT Southwestern, MD Anderson Cancer Center, and other major healthcare systems.
The CNSide platform is designed to identify tumor cells that have metastasized to the central nervous system, demonstrating 92% sensitivity and 95% specificity. The diagnostic tool has influenced treatment decisions in over 90% of cases and has been validated through more than 11,000 tests performed at over 200 U.S. cancer institutions since 2020.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
